Subscribe to the Antiviral InteliStrat Database

You need to be a member to get access to the database. Many options are available for subscribing along with subscription rates, as described on the Services page.


Below is a sample of information available upon subscribing to the database. This includes detailed product files that can be visualized by clicking on the products name appearing in the grid.


Log into your account

If you already have an account, please log in.

If you do not have an account. Please subscribe.

Database Sample

  Sponsor(s) Product Type of product Order Mode of action Viral family Virus Status-1 Status-2
Sanofi Pasteur / Sanofi Aventis (global presence)  Dengvaxia®
ChimeriVax-Dengue; ChimeriVax Dengue; CYD Dengue; CYD-TDV; CYD TDV
Vaccine  Recombinant, viral expr vector  Flaviviridae  Dengue virus  Market  Approved for market in Mexico (Dec. 2015), Philippines (Dec. 2015), Brazil (Dec. 2015), Salvador (Jan. 2016), EU (Dec. 19, 2018), USA (May 2019); Filings for marketing authorization completed in several countries endemic for Dengue Fever virus; See Rema 
Argos Therapeutics (formerly Merix Bioscience; USA)  AGS-004
AGS004; AGS 004; Arcelis
Vaccine  Other  Retroviridae  HIV (Human Immunodeficiency virus)  Phase II  2 Phase II trials completed (2011 and 2015) 
GlaxoSmithKline (GSK; global presence)  Retrovir®
Zidovudine; Azidothymidine; AZT; BW A509U; Zydowin
Inhibitor  NRTI  Retroviridae  HIV (Human Immunodeficiency virus)  Market  Approved for market in US (Mar. 19, 1987) and other markets 
Pharmacor (acquired by Procyon/Ambrilia Biopharma; Canada) (no longer in operation)  P-1946
P1946; P 1946
Inhibitor  PI  Retroviridae  HIV (Human Immunodeficiency virus)  Preclinical  Lead compound 
TaiMed Biologics (Taiwan, USA)  Trogarzo™
Ibalizumab; Ibalizumab-uiyk; TNX-355; TNX355; TNX 355; Hu5A8; TMB-355; TMB355; TMB 355
Antibodies  EI  Retroviridae  HIV (Human Immunodeficiency virus)  Market  Orphan Drug status; Fast track status; Breakthrough Therapy Designation (Feb. 2015); Priority Review status granted by FDA (Jun. 2017), and FDA approval for US market granted on Mar. 06, 2018; See Remarks 
Novartis (global presence)  Focetria®
Focetria® A(H1N1); Focetria A(H1N1); Focetria A/H1N1; Influenza A (H1N1) 2009 Monovalent Vaccine
Vaccine  Non-recombinant protein vaccine  Orthomyxoviridae  Swine Influenza virus  Market  Approved by EMEA for distribution in EU (Sept. 29, 2009) under control of health authorities and governments; WHO-Prequalification status; No longer available (2015); See Remarks 
Abbott / AbbVie (global presence)  A-837093
A-837,093; A837093; A 837093
Inhibitor  RNA Pol IN  Flaviviridae  HCV (Hepatitis C virus)  Preclinical  No further development 
Abbott / AbbVie (global presence)  Paritaprevir
Veruprevir; ABT-450; ABT450; ABT 450
Inhibitor  PI  Flaviviridae  HCV (Hepatitis C virus)  Market  Approved for market in US (Dec. 2014)and other markets as part of combination therapy called Viekira Pak; See Remarks 
Novavax (USA) (formerly DynCorp)  ResVax™
RSV-F VLP vaccine; RSV vaccine; RSV F-VLP vaccine; RSV F VLP vaccine; RSV F vaccine
Vaccine  Recombinant protein vaccine  Paramyxoviridae  RSV (Respiratory Syncytial virus)  Phase III  New Phase III initiated after failure of a first Phase III trial, Jan. 2017; Fast track designation granted by FDA (2016); See Remarks 
Janssen Therapeutics (formerly Tibotec) / Janssen Pharmaceuticals / Johnson & Johnson (global presence)  TMC353121
TMC-353121; TMC 353121
Inhibitor  EI  Paramyxoviridae  RSV (Respiratory Syncytial virus)  Preclinical   

Products: 1 - 10 (Total: 10)